An interventional study of Health MPowerment App in HIV Infections, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged 14 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Emory University · Not applicable, Interventional, and Supportive care
Among 19 studies in HIV Infections by Emory University — 4 open to participants now, 6 under way, none of them phase 3. HIV Infections · Emory University.
Among the 19 studies in HIV Infections by Emory University, this one is the 17th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 9 with no phase, and was the 19th registered.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
Browse HIV Infections studies →4 of the 19 studies in HIV Infections by Emory University are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in South Africa
Emory University · Sites in Kenya
Emory University · Sites in United States
By country, each count listing its studies:
Of the 158 HIV Infections studies recruiting now, 104 (66%) set no upper age limit and 41 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 14 Years to 21 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 10 is below the median of 80 across 3,489 interventional studies indexed under HIV Infections.
Median enrollment 63 across the 17 interventional studies, 60 across the 2 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,405 studies on the registry; 225 are open to participants now.
Of its 237 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.
4 of the studies in HIV Infections by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT07535346Emory UniversityIntegrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta | 2027-04 |
| NCT07226323Emory UniversityTesting the WeCare Intervention to Address Mental Health and Medication Adherence Challenges Among MSM in South Africa | 2027-07-31 |
| NCT06205368Emory UniversityEvaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men | 2027-09 |
Among the 19 studies in HIV Infections by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study applies Social Cognitive Theory to develop behavioral interventions promoting PrEP adherence. It seeks to adapt and test the enhanced HMP app for feasibility and acceptability among Black adolescents and young adults (AYAs) and adult supports.
HIV pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV infections, reducing the risk by over 90%. However, adherence among AYAs remains suboptimal, with only 34% maintaining adherence at 48 weeks. Studies suggest that adult support can improve adherence in pediatric HIV treatment, but this approach has not been systematically evaluated for PrEP use in AYAs. Prior research indicates that Black AYAs and their families are open to incorporating adult support for PrEP adherence. Given the success of mobile health (mHealth) interventions in promoting sexual health, this study aims to enhance the HealthMPowerment (HMP) app-an existing mHealth platform designed for HIV prevention-to facilitate dyadic communication between Black AYAs and trusted adult support persons.
The study addresses the high rates of HIV among Black adolescents and young adults (AYAs) in metro Atlanta, Georgia, where AYAs (ages 13-24) account for 21% of new HIV diagnoses, with Black gay and bisexual males, transgender individuals, and heterosexual young women being disproportionately affected. Nearly half of new infections occur in rural areas. The U.S. Department of Health and Human Services Ending the HIV Epidemic initiative prioritizes four counties in metro Atlanta (Cobb, DeKalb, Fulton, and Gwinnett) as geographic hotspots, emphasizing the need for patient-centered interventions to reduce HIV incidence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
positive Inability to provide consent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants (AYAs and support persons) will receive a demonstration of the app, including all of its features. All participants will use the app for 6 months. Each dyad of participants will be instructed to use the app to communicate with each other and AYAs will be instructed to use the app to keep track of their PrEP. Data from the medication tracker will be collected at 1-, 3-, and 6-months
Behavioral: Health MPowerment App
A mobile health app designed to facilitate increased PrEP use and adherence among AYAs
Acceptability/Usability
The study evaluates an app's impact through post-intervention interviews, focusing on user experience, ethical concerns, and future usage intentions. It explores burden, satisfaction, attitudes, and how the app influences communication and adherence. Sekhon's Theoretical Framework of Acceptability will be utilized to measure this outcome.
Time frame: 1 month, 3 months, and 6 months
Feasibility: Communication
Communication between adolescents and young adults (AYA) and support person (i.e., Experience using chat features; Experience using forums). A modified version of Structured Assessment of FEasibility (SAFE) will be utilized to measure this outcome.
Time frame: 1 month, 3 months, and 6 months
Medication Adherence Tracker
This will be measured by analyzing the percent of dates with data entered into the medication tracker and correlating that data with reasons why participants did not take their medication (when applicable)
Time frame: 1 month, 3 months, and 6 months
Data Usage
This will be measured by comparing the amount of time (minutes) spent using distinct features of the app (e.g. forums, educational resources, avatars, side effect trackers, chat features)
Time frame: 1 month, 3 months, and 6 months
Plan to share: Yes — The following data will be shared: Data acceptability and feasibility measures as analyzed via interviews and surveys, and data app usage
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: May 2027 onwards
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Apr 2027, 0 months later.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 0 months is below that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.